Slide 1: Transaction and Workflow Engine Operating Across Healthcare and Financial Rails
Transaction and Workflow Engine Operating Across Healthcare and Financial Rails Planet MicroCap Las Vegas 2026 June 17, 2026
Slide 2: Disclaimers & Safe Harbor
2 Disclaimers & Safe Harbor NASDAQ: PAYS Forward-looking statements Non-GAAP financial measures This presentation contains "forward-looking statements" within the meaning of Section This presentation contains non-GAAP financial measures, including Adjusted EBITDA, Adjusted 27A of the Securities Act
Slide 3: Investment Highlights
3 Investment Highlights Revenue ($M) Operating Income ($M) Adj. EBITDA ($M) Transactional and Workflow Engine Operating +40.5% YoY 7.4× Growth +107.3% YoY Across Healthcare and Financial Rails $82.0M $7.4M $19.9M • ~45% U.S. plasma market share – a defensible position built over a decade $58.4M • Ph
Slide 4: One Operational Platform. Two Growing Businesses.
4 One Operational Platform. Two Growing Businesses. NASDAQ: PAYS Fixed infrastructure is in place – every incremental sale, on either side, scales on the same base. Plasma Pharma: Patient Affordability Donor Compensation Program Management Copay Program Management Donor payments – the cash-generatin
Slide 5: Pharma: Patient Affordability Solutions
5 Pharma: Patient Affordability Solutions NASDAQ: PAYS Patient access, program integrity – delivered as one seamless experience. Continuity for the patient What the Patient Experiences A program that transitions to Paysign is a handoff the patient never notices. Fills their Rx Uses the card Walks ou
Slide 6: The Maximizer & Accumulator Problem
6 The Maximizer & Accumulator Problem NASDAQ: PAYS PBMs are diverting the manufacturer assistance that should be helping patients stay on therapy. How Copay Programs Should Work Manufacturer funds the copay Patient uses the copay card at Payment credits the patient's Patient gets (and stays) on 1 pr
Slide 7: Dynamic Business Rules – The Paysign Moat
7 Dynamic Business Rules – The Paysign Moat NASDAQ: PAYS Protecting patient access and manufacturer programs – at the transaction level, invisibly. The Detection Gap detection accuracy · maximizer tactics Paysign Dynamic Business Rules: accuracy and savings on the FIRST fill 97% Funds at Risk: what
Slide 8: Patient Affordability: By the Numbers
8 Patient Affordability: By the Numbers NASDAQ: PAYS Compounding growth across revenue, program count, and mix share – on infrastructure already in place. Quarterly PA Revenue ($M) Headline Results $15.7 $9.6 +116.9% $8.6 TTM though Q1FY2026 PA revenue growth (YoY) $7.8 $7.9 $2.4 $2.7 $3.3 $4.3 $41.
Slide 9: Plasma: Donor Payment & Engagement
9 Plasma: Donor Payment & Engagement NASDAQ: PAYS Instant donor payments, integrated software – built for the plasma collection workflow. What the Donor Experiences Retention Drives Supply Donates plasma Paid instantly Returns to donate 1 At a participating collection 2 Funds on the Paysign card 3 R
Slide 10: Plasma: By the Numbers
10 Plasma: By the Numbers NASDAQ: PAYS Market-leading scale, mature recurring revenue, and room to grow – the foundation beneath the platform. Annual Plasma Revenue ($M) Plasma at Scale Guidance 554 ~$54M $43.9M $45.6M plasma facilities served · at 5/12/26 +4.0% +16.2% 8.4M total cardholders on plat
Slide 11: Apherion: The Operating Platform for Plasma & Blood Collection
11 Apherion : The Operating Platform for Plasma & Blood Collection NASDAQ: PAYS Modular, cloud-based platform for engagement, operations, payments, and compliance. Platform Architecture Why This Matters 01 Modular SaaS Donor experience Apherion Connect Apherion Journey Recurring software on top of p
Slide 12: The Paysign Competitive Moat
12 The Paysign Competitive Moat NASDAQ: PAYS Four forces that reinforce each other – and compound Paysign’s strategic position. 01 / Proprietary 02 / Scale 03 / Integrated 04 / Regulatory Dynamic Market Payments High-Barrier Business Rules Leadership + Software Compliance 97% first-fill accuracy – n
Slide 13: Market Opportunity
13 Market Opportunity NASDAQ: PAYS Two structurally growing U.S. markets – meaningful runway in both. Plasma collection payments Patient affordability Large, mature, structurally growing. Growing, complex, under-served. U.S. collects ~66% of global plasma – feedstock for life-saving therapies Rising
Slide 14: Financial Profile
14 Financial Profile NASDAQ: PAYS Compounding growth, expanding margins, and a capital-light balance sheet. Top-line growth Operating leverage +40.5% 2.6× FY2025 revenue growth · $58.4M → $82.0M Adj. EBITDA growth vs. revenue growth (FY2025) 5 consecutive years of double-digit growth Revenue +40.5%
Slide 15: Revenue by Business
15 Revenue by Business NASDAQ: PAYS From plasma-dominant to a balanced two-engine platform. Annual revenue by business ($m) Growth by business Plasma ~$108.5M Plasma Patient Affordability FY2025: +4.0% · FY2026E: ~+18% Other Steady mid-single-digit compounding on a mature, recurring $82.0M base. ~$5
Slide 16: Margin Profile
16 Margin Profile NASDAQ: PAYS Stable gross margin, improving SG&A ratio – compounding EBITDA margin expansion. Adj. EBITDA margin (%) Drivers of expansion Gross Margin 60–62% Gross Margin 59.4% (FY2026E) (FY2025) Gross margin Gross Margin 55.1% (FY2024) 59.4% FY2025 · stable at mature levels SG&A l
Slide 17: Condensed Income Statement
17 Condensed Income Statement NASDAQ: PAYS Quarterly Full year ($ in millions, except per-share) Q1 2026 Q1 2025 FY 2025 FY 2024 Revenue $28.0 $18.6 $82.0 $58.4 Gross Profit $18.2 $11.7 $48.7 $32.2 Gross Margin % 65.0% 62.9% 59.4% 55.1% SG&A (excluding D&A) $8.9 $7.4 $33.0 $25.2 SG&A / Revenue % 31.
Slide 18: 2026 Outlook
18 2026 Outlook NASDAQ: PAYS Company guidance – FY 2026 Revenue Adj. EBITDA $106.5M – $110.5M $30.0M – $33.0M +30% to +35% YoY +51% to +66% YoY FY 2025 Actual FY 2025 Actual $82.0M $19.9M Growth from FY2025 Growth from FY2025 +$24.5M to +$28.5M +$10.1M to +$13.1M • Roughly balanced plasma / PA split
Slide 19: Leadership Team
19 Leadership Team NASDAQ: PAYS Mark Newcomer Jeff Baker President & Chief Executive Officer Chief Financial Officer • Co-founded Paysign in 2001; led the company through its 2018 NASDAQ public • CFO since 2021; previously EVP of M&A at InComm Payments and Chief listing and subsequent scaling Develo
Slide 20: Independent Directors
20 Independent Directors NASDAQ: PAYS Dan Henry Bruce Mina Jeffrey Newman Dennis Triplett Chairman Independent Director Independent Director Independent Director Co-founder of Euronet Worldwide CPA, founder, and managing Former General Counsel for Euronet Former bank executive and chairman (NASDAQ:
Slide 21: Investment Highlights
21 Investment Highlights NASDAQ: PAYS FY 2025 results +40.5% +107.3% ~45.5% +116.9% Revenue Growth Adj. EBITDA Growth U.S. Plasma Market Share PA Revenue Growth $58.4M → $82.0M $9.6M → $19.9M 554 facilities as of 5/12/26 TTM: $18.9M → $40.9M 2026 Guidance Revenue Adj. EBITDA $106.5M – $110.5M $30.0M